BACKGROUND: Pompe disease is a rare, autosomal-recessive disorder which results from a defect in the lysosomal enzyme acid alpha-glucosidase (GAA). The onset of this disease is highly variable, with infantile types being the most severe. Traditionally, lymphocytes, fibroblasts or muscle biopsies were necessary for enzyme activity measurement, because these materials do not express maltase-glucoamylase (MGA) that interferes with the assay. Recently, acarbose was found to inhibit MGA activity selectively, so that dried blood became accessible for GAA assessment. AIM: To evaluate the diagnostic efficacy of GAA measurement in dried blood specimens (DBSs) in comparison with lymphocytes. If DBSs provided reliable results, the diagnosis of Pompe disease could be facilitated, and high-throughput screening would become possible. METHODS AND RESULTS: GAA activity was measured in DBSs of known patients at pH 3.8 (with and without acarbose) and at pH 7.0. Additionally, lymphocytes were obtained from the same patients, and the enzyme activity was determined at pH 4 to pH 7. In total, seven infantile patients and 29 patients with late-onset variants were investigated. All patients were reliably identified by both methods. Furthermore, a simplified protocol was established for neonatal screening. CONCLUSION: The fluorometric technique for the assessment of GAA activity in DBS provides a reliable diagnosis for all variants of Pompe disease. The assay protocol could be simplified for neonatal screening, without increasing the false positive rate significantly or burdening the laboratory with time-consuming procedures.
BACKGROUND: Pompe disease is a rare, autosomal-recessive disorder which results from a defect in the lysosomal enzyme acid alpha-glucosidase (GAA). The onset of this disease is highly variable, with infantile types being the most severe. Traditionally, lymphocytes, fibroblasts or muscle biopsies were necessary for enzyme activity measurement, because these materials do not express maltase-glucoamylase (MGA) that interferes with the assay. Recently, acarbose was found to inhibit MGA activity selectively, so that dried blood became accessible for GAA assessment. AIM: To evaluate the diagnostic efficacy of GAA measurement in dried blood specimens (DBSs) in comparison with lymphocytes. If DBSs provided reliable results, the diagnosis of Pompe disease could be facilitated, and high-throughput screening would become possible. METHODS AND RESULTS:GAA activity was measured in DBSs of known patients at pH 3.8 (with and without acarbose) and at pH 7.0. Additionally, lymphocytes were obtained from the same patients, and the enzyme activity was determined at pH 4 to pH 7. In total, seven infantile patients and 29 patients with late-onset variants were investigated. All patients were reliably identified by both methods. Furthermore, a simplified protocol was established for neonatal screening. CONCLUSION: The fluorometric technique for the assessment of GAA activity in DBS provides a reliable diagnosis for all variants of Pompe disease. The assay protocol could be simplified for neonatal screening, without increasing the false positive rate significantly or burdening the laboratory with time-consuming procedures.
Authors: B Winchester; D Bali; O A Bodamer; C Caillaud; E Christensen; A Cooper; E Cupler; M Deschauer; K Fumić; M Jackson; P Kishnani; L Lacerda; J Ledvinová; A Lugowska; Z Lukacs; I Maire; H Mandel; E Mengel; W Müller-Felber; M Piraud; A Reuser; T Rupar; I Sinigerska; M Szlago; F Verheijen; O P van Diggelen; B Wuyts; E Zakharova; J Keutzer Journal: Mol Genet Metab Date: 2007-12-19 Impact factor: 4.797
Authors: Toshika Okumiya; Joke L M Keulemans; Marian A Kroos; Nadine M E Van der Beek; Marijke A Boer; Hiroaki Takeuchi; Otto P Van Diggelen; Arnold J J Reuser Journal: Mol Genet Metab Date: 2005-12-15 Impact factor: 4.797
Authors: B Bembi; E Cerini; C Danesino; M A Donati; S Gasperini; L Morandi; O Musumeci; G Parenti; S Ravaglia; F Seidita; A Toscano; A Vianello Journal: Neurology Date: 2008-12-02 Impact factor: 9.910
Authors: Haoyue Zhang; Helmut Kallwass; Sarah P Young; Cortney Carr; Jian Dai; Priya S Kishnani; David S Millington; Joan Keutzer; Yuan-Tsong Chen; Deeksha Bali Journal: Genet Med Date: 2006-05 Impact factor: 8.822
Authors: Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson Journal: Genet Med Date: 2006-05 Impact factor: 8.822
Authors: Zoltan Lukacs; Paulina Nieves Cobos; Stephan Wenninger; Tracey A Willis; Michela Guglieri; Marc Roberts; Rosaline Quinlivan; David Hilton-Jones; Teresinha Evangelista; Stephan Zierz; Beate Schlotter-Weigel; Maggie C Walter; Peter Reilich; Thomas Klopstock; Marcus Deschauer; Volker Straub; Wolfgang Müller-Felber; Benedikt Schoser Journal: Neurology Date: 2016-05-11 Impact factor: 9.910
Authors: Stephanie Shifra Weinreich; Tessel Rigter; Carla Geertruida van El; Wybo Jan Dondorp; Pieter Johannes Kostense; Ans T van der Ploeg; Arnold J J Reuser; Martina Cornelia Cornel; Marloes Louise Catharina Hagemans Journal: Orphanet J Rare Dis Date: 2012-03-14 Impact factor: 4.123
Authors: Zoltan Lukacs; Petra Oliva; Paulina Nieves Cobos; Jacob Scott; Thomas P Mechtler; David C Kasper Journal: Int J Neonatal Screen Date: 2020-12-21